Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
Go back to Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 27.29 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.29 | 52 Week High | $42.49 | |||
| Open | $27.29 | 52 Week Low | $16.64 | |||
| Day High | $27.29 | P/E | N/A | |||
| Day Low | $27.29 | EPS | $-0.42 | |||
| Volume | 307 | |||||
